The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial

Ronald de Wit; J Herrstedt; B Rapoport; AD Carides; J Guoguang-Ma; M Elmer; C Schmidt; JK Evans; KJ Horgan

doi:10.1016/j.ejca.2003.08.028

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial

Ronald de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, C Schmidt, JK Evans, KJ Horgan

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

153 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	403-410
Number of pages	8
Journal	European Journal of Cancer
Volume	40
DOIs	https://doi.org/10.1016/j.ejca.2003.08.028
Publication status	Published - 2004

Access to Document

10.1016/j.ejca.2003.08.028

http://hdl.handle.net/1765/66398

Cite this

de Wit, R., Herrstedt, J., Rapoport, B., Carides, AD., Guoguang-Ma, J., Elmer, M., Schmidt, C., Evans, JK., & Horgan, KJ. (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial. European Journal of Cancer, 40, 403-410. https://doi.org/10.1016/j.ejca.2003.08.028

de Wit, Ronald ; Herrstedt, J ; Rapoport, B ; Carides, AD ; Guoguang-Ma, J ; Elmer, M ; Schmidt, C ; Evans, JK ; Horgan, KJ. / The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial. In: European Journal of Cancer. 2004 ; Vol. 40. pp. 403-410.

@article{0d9691c57c43473298799142eb2feb07,

title = "The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial",

author = "{de Wit}, Ronald and J Herrstedt and B Rapoport and AD Carides and J Guoguang-Ma and M Elmer and C Schmidt and JK Evans and KJ Horgan",

year = "2004",

doi = "10.1016/j.ejca.2003.08.028",

language = "Undefined/Unknown",

volume = "40",

pages = "403--410",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

de Wit, R, Herrstedt, J, Rapoport, B, Carides, AD, Guoguang-Ma, J, Elmer, M, Schmidt, C, Evans, JK & Horgan, KJ 2004, 'The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial', European Journal of Cancer, vol. 40, pp. 403-410. https://doi.org/10.1016/j.ejca.2003.08.028

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial. / de Wit, Ronald; Herrstedt, J; Rapoport, B; Carides, AD; Guoguang-Ma, J; Elmer, M; Schmidt, C; Evans, JK; Horgan, KJ.

In: European Journal of Cancer, Vol. 40, 2004, p. 403-410.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial

AU - de Wit, Ronald

AU - Herrstedt, J

AU - Rapoport, B

AU - Carides, AD

AU - Guoguang-Ma, J

AU - Elmer, M

AU - Schmidt, C

AU - Evans, JK

AU - Horgan, KJ

PY - 2004

Y1 - 2004

U2 - 10.1016/j.ejca.2003.08.028

DO - 10.1016/j.ejca.2003.08.028

M3 - Article

VL - 40

SP - 403

EP - 410

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial. European Journal of Cancer. 2004;40:403-410. https://doi.org/10.1016/j.ejca.2003.08.028